1. Home
  2. Products
  3. Customized ADCs
  4. ERBB2
  5. Anti-ERBB2 (Trastuzumab)-DOX ADC

Anti-ERBB2 (Trastuzumab)-DOX ADC (CAT#: ADC-W-571)

This ADC product is comprised of an anti-ERBB2 monoclonal antibody (Trastuzumab) conjugated via a linker to DOX. The DOX is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DOX binds to DNA, causes DNA damage.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • ERBB2
  • Alternative Names
  • ERBB2; erb-b2 receptor tyrosine kinase 2; NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; receptor tyrosine-protein kinase erbB-2; herstatin; p185erbB2; proto-oncogene Neu; c-erb B2/neu protein; proto-oncogene c-ErbB-2; metastatic lymph node gene 1
  • Target Entrez Gene ID
  • 2064
  • Overview
  • This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
  • Overview
  • Humanized Anti-ERBB2 lgG1 Antibody, Trastuzumab-Fab
  • Generic name
  • Trastuzumab-Fab
  • Species Reactivity
  • Human
  • Name
  • thiomaleamicacids-p-aminobenzyloxycarbonyl
  • Name
  • doxorubicin
  • Description
  • Doxorubicin is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.

For Research Use Only. NOT FOR CLINICAL USE.

Related Products

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform
Reviews
Development of Monoclonal Antibodies
Literature
CAMouse™-Fully Human Antibody Generation Platform
Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-571. Click the button above to contact us or submit your feedback about this product.

Quick Links

ADC Toxins
Drug-linker Complexes
Customized ADCs
Anti-Ab ADCs

Other Products

Same Target Same Payload
CAT# Product Name Linker Payload
ADC-W-1117 Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC MC-Vc-PAB-DMEA-(PEG2) duocarmycin SA
ADC-W-1113 Anti-ERBB2 (Pertuzumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-2595 Anti-ERBB2 (Trastuzumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-1115 Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-1114 Anti-ERBB2 (Pertuzumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
CAT# Product Name Linker Payload
ADC-W-479 Anti-CD74-SMCC-Dox ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) Doxorubicin
ADC-W-578 Anti-CD74-MCC-Dox ADC MCC (Maleimidomethyl cyclohexane-1-carboxylate) doxorubicin
ADC-W-503 Anti-EGFR-EDC/NHS-Dox ADC EDC/NHS(1-ethyl-3-(3-diaminopropyl)carbodiimide/N-hydroxysuccinimide) Doxorubicin
ADC-W-423 Anti-FUT3-hydrazone-doxorubicin ADC hydrazone doxorubicin
ADC-W-376 Anti-CD70-β-glucuronide-doxorubicin ADC-5 β-glucuronide linker doxorubicin

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.